Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

about

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

Item

http://www.wikidata.org/entity/Q48316515

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@en

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@nl

type

Item

label

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@en

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@nl

prefLabel

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@en

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@nl

P1476

Evaluation of a New Fully Automated Assay for Plasma Intact FGF23.

@en

P2093

Anya Rothenbuhler

http://www.w3.org/2001/XMLSchema#string

Dominique Prié

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Souberbielle

http://www.w3.org/2001/XMLSchema#string

Marie-Liesse Piketty

http://www.w3.org/2001/XMLSchema#string

Philippe Chanson

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations

How fibroblast growth factor 23 works

Regulation of fibroblast growth factor-23 signaling by klotho

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

FGF23 induces left ventricular hypertrophy

P2888

s00223-017-0307-y

P304

510-518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00223-017-0307-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Etienne Cavalier

Pierre Delanaye

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28761972

http://www.w3.org/2001/XMLSchema#string